Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
In Brief

UAMS Winthrop P. Rockefeller Cancer Institute receives five NCI grants

June 28, 2024
Vol.50 No.26
Clinical Roundup

Tai Chi reduces risk of inflammatory disease, treats insomnia among breast cancer survivors

June 28, 2024
Vol.50 No.26
“Father of tamoxifen” V. Craig Jordan dies at 76
FreeObituary

“Father of tamoxifen” V. Craig Jordan dies at 76

June 14, 2024
Vol.50 No.24
By MD Anderson Cancer Center staff
In an interview and a memoir, V. Craig Jordan spoke about his life and SERMs
FreeIn the Archives

In an interview and a memoir, V. Craig Jordan spoke about his life and SERMs

June 14, 2024
Vol.50 No.24
Clinical Roundup

Hydroxychloroquine + lapatinib may reduce breast cancer metastases

June 14, 2024
Vol.50 No.24
In Brief

Dennis Slamon receives Szent-Györgyi Prize from National Foundation for Cancer Research

June 07, 2024
Vol.50 No.23
In Brief

Susan Bullman, Xi Chen named associate members of MD Anderson’s Allison Institute

June 07, 2024
Vol.50 No.23
Clinical Roundup

Enhertu demonstrated median PFS of 13.2 months in IHC 1+ or IHC 2+/ISH- metastatic breast cancer in phase III trial

June 07, 2024
Vol.50 No.23
In Brief

COTA, Baptist Health South Florida, PreciseDx collaborate on AI-based test for IBC recurrence

May 31, 2024
Vol.50 No.22
In Brief

Personalis, Tempus collaborate to commercialize MRD test

May 31, 2024
Vol.50 No.22

Posts navigation

Previous1…131415…33Next

Trending Stories

  • Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
    PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”
  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
  • No need for a speculum? A new era of HPV screening
  • Most Favored Nation drug pricing could put China on top
  • Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
    A kit for at-home unsupervised self-collection clears FDA finish line

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account